---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-006719"
form_type: "8-K"
ticker: "INCY"
cik: "0000879169"
company_name: "INCYTE CORP"
filed_at: "2022-05-03T23:59:59+00:00"
generated_at: "2026-06-26T01:48:15.081034+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Incyte Q1 2022 revenue $733M (+21%); Jakafi guidance raised; Opzelura uptake strong

## Summary
- Total product & royalty revenues $728M (+20% YoY); GAAP net income $38M ($0.17 EPS); non-GAAP net income $123M ($0.55).
- Jakafi net product rev $544M (+17% YoY); full-year guidance raised to $2.33-$2.40B from $2.3-$2.4B.
- Opzelura >38,000 new patients in Q1; 146M lives covered; vitiligo sNDA under FDA review, PDUFA July 18.
- Pemazyre approved in China; ruxolitinib QD NDA on track H1 2022; positive CHMP opinion for ruxolitinib in GVHD.
- Cash, equivalents & securities $2.5B as of March 31, 2022.

## SEC filing metadata
- accession: 0001558370-22-006719
- form_type: 8-K
- ticker: INCY
- cik: 0000879169
- company_name: INCYTE CORP
- filed_at: 2022-05-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879169/000155837022006719/0001558370-22-006719-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879169/000155837022006719/incy-20220503x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-006719
- JSON: https://secwatch.observer/filing/0001558370-22-006719.json
- Plain text: https://secwatch.observer/filing/0001558370-22-006719.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.